

BIOPHYSICAL CHEMISTRY AND PHYSICAL AND CHEMICAL BIOLOGY

Drug Delivery by (5,5) Armchair SWCNT in Bone Tissue through Adsorption of Protein-Bisphosphonate Agents: Metal Chelation Study of Mg^{2+} , Ca^{2+} , Sr^{2+}

Somayeh Khosravi^a, Majid Monajjemi^{b,*}, Fatemeh Mollaamin^{c,**},
Karim Zare^a, and Masoumeh Sayadian^d

^a Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran

^b Department of Chemical Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran

^c Department of Biomedical Engineering, Faculty of Engineering and Architecture,
Kastamonu University, Kastamonu, Turkey

^d Department of Chemistry, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran

* e-mail: maj.monajjemi@iauctb.ac.ir

** e-mail: smollaamin@gmail.com

Received June 26, 2022; revised October 1, 2022; accepted October 3, 2022

Abstract—Single-walled carbon nanotube (SWCNT) joint to some ligands of bisphosphonate agents including 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 chelated to metal cations of Mg^{2+} , Ca^{2+} , Sr^{2+} has been investigated due to the direct electron transfer principle using density functional theory (DFT) methods. Bisphosphonate medications can be applied in prohibition the damage of bone density and the remedy of bone illnesses such as osteoporosis. As the metal chelating of phosphonate groups are nearby large with six O atoms possessing the high negative charge, these compounds are active towards producing the chelated complexes through drug design method. In this work, it has been accomplished the B3LYP/6-311+G(d,p)/LANL2DZ to estimate the susceptibility of SWCNT for adsorbing 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 chelated to metal cations of Mg^{2+} , Ca^{2+} , Sr^{2+} through nuclear magnetic resonance and thermodynamic parameters. Therefore, the data explained that the feasibility of using SWCNT and bisphosphonate agents becomes the norm in metal chelating of delivery system which has been selected through 5AEL- Mg^{2+} , 5AEL- Ca^{2+} , 5AEL- Sr^{2+} ; 5AFX- Mg^{2+} , 5AFX- Ca^{2+} , 5AFX- Sr^{2+} ; 4QPF- Mg^{2+} , 4QPF- Ca^{2+} , 4QPF- Sr^{2+} ; 3DYG- Mg^{2+} , 3DYG- Ca^{2+} , 3DYG- Sr^{2+} ; 2F92- Mg^{2+} , 2F92- Ca^{2+} , 2F92- Sr^{2+} ; 2I19- Mg^{2+} , 2I19- Ca^{2+} , 2I19- Sr^{2+} using DFT method due to physico-chemical properties of NMR and IR methodologies.

Keywords: (5,5) armchair SWCNT, protein-bisphosphonate, 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19, metal chelating, Mg^{2+} , Ca^{2+} , Sr^{2+} , IR, NMR, DFT

DOI: 10.1134/S0036024423050254

INTRODUCTION

Bone tissue tolerates constant rebuilding and achieves the equilibrium by osteoblasts producing bone and osteoclasts destroying bone. The compounds of bisphosphonates keep from the digestion of bone by pushing osteoclasts to bear cell death or the apoptosis which diminish the velocity of bone destroying [1]. The principal impact of the active bisphosphonates is to prevent bone resorption. In fact, these structures manifest to be really strong inhibitors of resorption when experimented in various conditions of in vivo and in vitro. Bisphosphonate compounds stop bone resorption produced by different reasons in cell and organ. They prevent forming the holes by isolated osteoclasts on mineral layers [2].

Generally, the physicochemical impacts of bisphosphonates are very close to those of pyrophosphate. Therefore, they prevent the formation, postpone the association, and decrease the dissolution of calcium phosphate compounds. All these impacts depend on the identified intention of these structures for solid-phase calcium phosphate, on the surface of which they attach extremely. This notable characteristic is the basis for the employment of these structures as skeletal markers in nuclear medicine and the foundation for their selective localization in bone when employed as the drugs. There is an attention to enhancing the bioavailability and duration of action of a drug to modify therapeutic consequences. Drug delivery technique is able to change a drug's pharmacokinetics and specificity by formulating it with vari-

ous ingredients, drug carriers, and medical equipment [3–12].

Nanomedicine covers a wide range of therapeutic applications, from nanoparticulate drug delivery systems including carbon nanotubes, layered double hydroxides, to in vitro (biosensor) and in vivo (imaging and implantable devices) diagnostics [13–18]. Nanomedicine in drug delivery is for achieving the improved delivery of water insoluble drugs, delivery of large macromolecule drugs to intracellular sites of action, and codelivery of two or more drugs or therapeutic agents for combination remedy [19–21]. Since the exploring CNTs in 1990s and the progress of their application in nanomedicine, these compounds are significant through their properties including rich electronic and thermal factors, great mechanical strength, high chemical stability, and extremely light weight [22–24]. These carriers indicate the capability for transferring the therapeutic agents such as proteins, DNA, antibodies and drugs on the external wall or by trapping in the cavity nanotubes as a capsule [25–27].

Nanotubes with their intrinsic properties have been considered potential candidates for drug delivery carriers. The capped ends of nanotubes may be opened up by oxidation, allowing for the insertion of molecules of interest inside the nanotube. Carbon nanotubes (CNTs) can easily penetrate cells, delivering drugs directly to the cytoplasm or nucleus [28–32].

CNTs are large molecules which are built by repeating pattern of sp^2 hybridized carbon atoms in a hexagonal composition, rolled into a cylinder of approximately 2.5–100 nm in diameter. CNTs are long and tubular fullerene structures which can be either single-walled (SWCNTs) or multiwalled (MWCNTs). SWCNTs are formed by a rolling single layer of graphite cylinder with a tube diameter of approximately 0.4–2 nm, but MWCNTs are multiple concentric cylindrical shells of graphite layers with the distance about 0.36 nm and diameters about 2–100 nm. Nanotubes conform to a perpendicular position with the cell membrane during uptake, perforating and diffusing through the lipid bilayer to enter the cytoplasm. Functionalized CNTs are easily internalized by cells through passive and endocytosis-independent mechanisms [33–44].

The bone cells in human body are gradually being continually taken away and substituted with new ones by osteoblast in the total life. The bisphosphonates behave by reducing osteoclast activity and then reducing the overturn of bone or replacement of the old bone cell. Since we start being old and in particular a disease, the bone is really being damaged or removed more quick than our body can substitute it. This makes the bones weakened, thin and much easily to break with even a small impact or a fall from a standing height. Therefore, bisphosphonate medications support us to keep the bone density and bone strength.

In fact, the most popular bisphosphonate medications have a rich tension for metal cations, among them Ca^{2+} , with which they can produce both soluble and insoluble compounds and aggregates, depending on the pH of the solution and the metal exist. The bisphosphonates are separated into chemical branches based on the side chains of R1 and R2. It is seen a central carbon in bisphosphonates with two side chains of R1, R2 and two phosphate branches which are bonded to Ca^{2+} through O^- of PO_3 groups for keeping a high amount of Ca^{2+} in bones of human body cells (Scheme 1) [45–51].

In this article, we have focused more on some ligands bisphosphonate agents including {2-[3-(hex-1-yn-1-yl)pyridinium-1-yl]ethane-1,1-diyl}bis(phosphonate) (5AEL), [1-hydroxy-2-(1-nonyl-1H-3 λ -5-imidazol-3-yl)ethane-1,1-diyl]bis(phosphonic acid) (5AFX), [1-fluoro-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid) (4QPF), 3-fluoro-1-(2-hydroxy-2,2-diphosphonoethyl)pyridinium (3DYG), 4-amino-1-hydroxybutane-1,1-diylbisphosphonate (2F92), [2-(pyridin-2-ylamino)ethane-1,1-diyl]bis(phosphonic acid) (2I19) which have been chelated with Mg^{2+} , Ca^{2+} , Sr^{2+} adsorbed onto (5,5) armchair SWCNT, respectively (Scheme 1).


Non N-containing bisphosphonates like clodronate, etidronate and tiludronate are discussed as the first generation of bisphosphonates which are simple molecules including single atoms or alkyl groups in side chains of R1 and R2 side chains having a weak inhibition impact on bone resorption [52].

Adding an amino group introduced starting the second generation of bisphosphonates which were more powerful such as pamidronate as the first one and other identical pursued where the situation of the nitrogen in the side chain was the clue to a more efficient medication [53].

Currently, third generation of bisphosphonates including N-containing of heterocyclic bisphosphonates like zoledronate and risedronate have been presented have displayed the most strong antiresorptive attributes [54, 55]. During the past years, third generation of bisphosphonates with enhancing bone affinity have been brought up for osteoporosis and other bone diseases treatment [56–58].

Since most patients these days obtain treatment with more potent N-containing bisphosphonates instead of the earlier non N-containing bisphosphonates [59, 60], we have concentrated on second and third generations of more recent classes of bisphosphonates (Scheme 1).

In this article, it has been investigated bisphosphonate agent of 2F92 as the second generation and 5AEL, 5AFX, 4QPF, 3DYG, 2I19 as third generation of bisphosphonates N-containing atoms in side chain of R2 for promoting osteoclast apoptosis (Scheme 1).



Scheme 1. Proposed mechanism of bisphosphonate–metal cation chelation of $\text{Mg}^{2+}/\text{Ca}^{2+}/\text{Sr}^{2+}$ through the O^- of two PO_3 (phosphonate) groups covalently linked to carbon for six ligands of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, and 2I19.

Moreover, the chelation of bisphosphonate agents of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 with Mg^{2+} , Ca^{2+} , Sr^{2+} has been investigated in this study by forming relatively stable drugs for adsorption onto (5,5) armchair CNT as a drug deliver (Scheme 2).

Thus, a series of quantum theoretical approaches has been accomplished for finding the optimized coordination of [bisphosphonate– Mg^{2+} , Ca^{2+} , Sr^{2+} –(5,5) armchair CNT] chelation with DFT method of computations using Gaussian09 program package (Fig. 1) [61].

THEORETICAL BACKGROUND AND COMPUTATIONAL METHOD


The density functional theory (DFT) is one of the most employed approximations of Hohenberg, Kohn, and Sham which permit the theoretical study of material properties [62]. DFT theory proves an advantageous method for predicting chemical systems, and in order to understand its similarities and differences to other computational methods employed [63–65].

In this study, the geometries were optimized at the framework of DFT using the three-parameter Becke's exchange [66] and Lee–Yang–Parr's correlation non-local functional [67], usually known as B3LYP method and basis sets of Inl2dz for metal cations of Mg^{2+} , Ca^{2+} , Sr^{2+} and $6\text{-311+G}(2d, p)$ for other atoms including H, C, N, O, F, P. Then, it has been described the electronic structure of adsorbed (5,5)

armchair SWCNT by bisphosphonate agents of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 chelated with Mg^{2+} , Ca^{2+} , Sr^{2+} for measuring physico-chemical properties (Fig. 1).

In this investigation, the Onsager model has been accomplished that was developed by Frisch, Wong and Wiberg utilizes spherical cavities. Even though this implies a less accurate description of the solute–solvent interface, this approximation simplifies the evaluation of energy formatives in geometry optimizations, and frequency analysis. Moreover, Cramer and Truhlar improved this model at dipole level [68–72]. In fact, a cavity must have a physical sense such as Onsager model, and has a mathematical ability as often happened in other descriptions of solvent impacts [73]. Specially, the cavity has to keep out the solvent and including its frontiers as the biggest probability part of the solute charge distribution [73].

Then, the gauge including atomic orbitals (GIAO) has been adopted to solve the gauge problem in the calculation of nuclear magnetic shielding for the complexes of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 chelated with Mg^{2+} , Ca^{2+} , Sr^{2+} adsorbed onto (5,5) armchair SWCNT using density functional theory (DFT) calculations. These new drugs have been used for new lower bone tendency of bisphosphonate drug design which is sufficient curing diseases identifying by abnormal bone resorption (4QPF). The progress of selective protein farnesyl transferase (FTase) and protein geranylgeranyl transferase (GGTase) inhibitors as



Scheme 2. Drug delivery of (5,5) armchair-SWCNT jointed with bisphosphonate agents of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 chelated with Mg²⁺, Ca²⁺, Sr²⁺ in the bone of human body.

anticancer therapeutic agents has explored 3DYG which is more efficient than current bisphosphonate drugs [74]. 2I19 is a solid-state (13)C, (15)N, and (31)P magic-angle sample spinning (MAS) NMR and quantum chemical study of several bisphosphonates as pure structures and bonded to FPPS for preparing data collection about side chain and phosphonate backbone protonation states when bind to the enzyme [75]. It has been indicated the consequences of many potential prenyl synthase inhibitors against *Trypanosoma brucei* farnesyl diphosphate synthase (TbFPPS) and against *T. brucei*, the causative agent of human African trypanosomiasis. 5AFX is one of the most powerful compounds lipophilic analogs of the bone resorption medication of zoledronate family [76]. Moreover, some researchers have accomplished on *T. brucei* farnesyl diphosphate synthase complexed with bisphosphonate BPH-597 by X-ray diffraction (5AEL) [77].

2F92 has been attained by solving the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen containing bisphosphonate (N-BP) medica-

tions of alendronate, ibandronate, pamidronate, zoledronate which prepare a new achieving of the mechanism of FPPS catalysis and inhibition [78].

A type of linkage of molecules to metal ions is chelation which defines the presence of two or more coordinated bonds between a multiple bonded ligand that are known chelating or sequestering agents and a single central metal atom. Chelation can be used between drugs and metal ions. For example, antibiotic drugs of the tetracycline and quinolone families are chelating agents of Fe²⁺, Ca²⁺, and Mg²⁺ ions [79, 80].

The chelation of bisphosphonates with cations in bone cells has been accomplished in this research by forming relatively stable complexes. Therefore, a group of quantum theoretical methods has been run for exploring the optimized structures of [bisphosphonate—cations of Mg²⁺/Ca²⁺/Sr²⁺] cluster chelation adsorbed onto the surface of (5,5) armchair SWCNT as the drug delivery method in human bone with thermodynamic calculations and nuclear magnetic resonance analysis using Gaussian 09 program software [61, 81].




Fig. 1. Adsorption of (a) 5AEL, (b) 5AFX, (c) 4QPF, (d) 3DYG, (e) 2F92, (f) 2I19 chelated with Ca^{2+} onto surface of (5,5) arm-chair CNT.

RESULTS AND DISCUSSION

CNTs are representing drug delivery platforms that can be functionalized with various biomolecules including antibodies, proteins, and DNA. This permits the particular targeted for transferring the special tissues, organs, or cells. These compounds can easily penetrate cells, delivering drugs directly to the cytoplasm or nucleus. Drug delivery systems improve the

pharmacological and therapeutic profile and efficacy of the drug and lower the occurrence of off-targets based on previous investigations [82].

NMR Analysis

The NMR data of isotropic (σ_{iso}), anisotropic shielding tensor (σ_{aniso}), and eigenvalues of chemical




Fig. 1. (Contd.)

shielding including σ_{11} , σ_{22} , σ_{33} for 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 adsorbed onto (5,5) arm-chair SWCNT, respectively, have been estimated (Table 1). The computed results have indicated the SCF GIAO magnetic shielding tensor in ppm for oxygen, nitrogen, fluorine, and phosphorus exploring the active site of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19

complexes of bisphosphonate agents as the drugs for osteoporosis and similar diseases cure. The calculations have been accomplished based on B3LYP/6-311+G(2d, p) level of theory using Gaussian 09 program software [61] and reported in Table 1.

The agents of 5AEL, 4PF, 2F92, 2I19 have approximately shown the identical behavior for various atoms

Table 1. SCF GIAO Magnetic shielding tensor for 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 in ppm chelated with cations at the adsorption site onto (5,5) armchair SWCNT

5AEL										
ppm	P2	P3	F4	O5	O6	O7	O8	O9	O10	N12
σ_{11}	120.7202	230.1554	435.8378	−845.9768	294.3757	235.7504	288.5618	−865.3928	282.1969	248.4936
σ_{22}	326.5601	360.4257	500.6499	−748.7844	339.1351	291.7178	343.2284	−381.6224	342.2235	254.9154
σ_{33}	586.9049	556.1500	504.5664	315.9052	403.8328	399.1250	398.4050	188.4803	396.1588	315.8979
σ_{iso}	344.7284	382.2437	480.3514	−426.2854	345.7812	308.8644	343.3984	−352.8449	340.1931	273.1023
σ_{aniso}	363.2648	260.8594	36.3226	1113.2858	87.0774	135.3909	82.5099	811.9879	83.9487	64.1933
5AFX										
ppm	P2	O3	P4	O5	O6	O7	O8	O9	N12	N15
σ_{11}	493.0153	347.4844	489.2774	367.7419	355.8661	195.7888	348.2661	348.5479	275.3916	252.7710
σ_{22}	535.3338	352.3542	543.7332	406.9306	384.9345	418.3030	379.6779	382.8813	297.8433	275.4504
σ_{33}	732.1662	405.8583	733.5645	478.7720	452.7585	452.7278	451.8487	459.2721	308.5416	280.4190
σ_{iso}	586.8385	368.5656	588.8584	417.8149	397.8530	355.6065	393.2642	396.9004	293.9255	269.5468
σ_{aniso}	217.9917	55.9390	217.0592	91.4357	82.3582	145.6819	87.8767	93.5575	21.9241	16.3083
4QPF										
ppm	N1	N9	P12	P13	F14	O15	O16	O17	O18	O19
σ_{11}	166.6870	−120.2309	371.2924	358.5225	406.5801	185.5508	276.8187	255.1893	185.6137	248.4056
σ_{22}	186.8310	80.5403	503.9686	498.5045	498.5821	332.2648	341.4780	322.6068	320.2219	337.7732
σ_{33}	291.5409	299.1759	577.4020	574.9991	567.7987	413.9534	417.7479	396.9123	394.3093	420.6935
σ_{iso}	215.0196	86.4951	484.2210	477.3420	490.9870	310.5896	345.3482	324.9028	300.0483	335.6241
σ_{aniso}	114.7819	319.0212	139.7714	146.4856	115.2175	155.0456	108.5995	108.0142	141.3915	127.6041
3DYG										
ppm	N3	P9	O10	P11	O12	O13	O14	O15	O16	F18
σ_{11}	272.2813	468.8130	307.8918	494.3100	330.5002	344.9279	175.2842	134.7427	326.4399	252.6723
σ_{22}	285.0418	583.9536	335.7405	574.0939	347.2339	351.1869	441.7081	417.8427	351.6728	454.1963
σ_{33}	304.0441	785.9277	410.4521	740.6575	428.8972	427.1516	497.7941	502.7569	456.0036	627.1797
σ_{iso}	287.1224	612.8981	351.3615	603.0205	368.8771	374.4222	371.5955	351.7808	378.0388	444.6828
σ_{aniso}	25.3825	259.5444	88.6359	206.4555	90.0302	79.0942	189.2979	226.4642	116.9472	273.7454
2F92										
ppm	P2	O3	P4	O5	O6	O7	O8	O9	O10	N14
σ_{11}	129.2678	327.5810	124.9174	285.3878	286.3320	−785.0432	287.4519	293.0829	−819.4334	273.0277
σ_{22}	324.5278	354.8863	341.2007	349.7245	344.7701	−699.3138	340.8483	341.6639	−729.5357	304.4646
σ_{33}	582.9983	397.7685	557.8503	424.7552	409.7726	323.2857	404.3027	404.4552	321.4145	317.5097
σ_{iso}	345.5979	360.0786	341.3228	353.2892	346.9582	−387.0238	344.2010	346.4007	−409.1849	298.3340
σ_{aniso}	356.1005	56.5349	324.7913	107.1991	94.2215	1065.4642	90.1526	87.0818	1095.8991	28.7636
2I19										
ppm	N1	N7	P10	P11	O12	O13	O14	O15	O16	O17
σ_{11}	−110.1587	266.0135	124.5896	317.4599	261.2164	277.3089	−1116.5483	−804.1879	294.1071	293.5133
σ_{22}	74.1505	291.1718	337.2575	380.6968	325.1630	323.4823	−164.9932	−716.7470	346.6974	346.7134
σ_{33}	340.0101	343.8731	583.1254	644.4727	371.1527	367.3362	432.5164	321.0844	410.5222	415.7349
σ_{iso}	101.3340	300.3528	348.3242	447.5432	319.1774	322.7091	−283.0084	−399.9502	350.4423	351.9872
σ_{aniso}	358.0142	65.2805	352.2019	295.3944	77.9630	66.9405	1073.2871	1081.5518	90.1200	95.6216




Fig. 2. The ^{13}C -NMR shifts of isotropic (σ_{iso}), anisotropic (σ_{aniso}), and eigenvalue shielding tensors (σ_{11} , σ_{22} , σ_{33}) calculated by level of theory B3LYP/6-311+G(2d, p) for (a) 5AEL and similar behavior of 4PF; (b) 3DYG and similar behavior for 5AFX in ppm adsorbed site onto (5,5) armchair SWCNT; (c) 2F92 and (d) 2119 through electronegative atoms of N, O, P, and F as the active positions in the structures of bisphosphonate agents.




Fig. 3. The ^1H -NMR of (a) 5AEL- Mg^{2+} , (b) 5AFX- Mg^{2+} , (c) 4QPF- Ca^{2+} , (d) 3DYG- Ca^{2+} , (e) 2F92- Sr^{2+} , and (f) 2I19- Sr^{2+} using SCF GIAO method NMR due to B3LYP function and 6-311+G(2d,p) basis set for metal cations of Mg^{2+} , Ca^{2+} , Sr^{2+} , and 6-311+G(2d,p) basis set for other elements.




Fig. 4. Calculated IR intensity (km/mol) versus frequency (cm^{-1}) through the IR spectra for (a) 2F92- Sr^{2+} and (b) 2I19- Sr^{2+} of bisphosphonate agents adsorbed onto (5,5) armchair SWCNT using 6-311+G(2d, p) calculations.

in the active sites of these compounds through the NMR properties (Fig. 2a). The bisphosphonate agents of 3DYG, 5AFX have also the similar fluctuation in the magnetic shielding tensor (Fig. 2b). Moreover, the ^{13}C -NMR measurements on 2F92 and 2I19 bisphosphonate agents have demonstrated the active sites of these compounds exploring the most electronegative atoms for adsorbed onto (5,5) armchair SWCNT which represent the maximal shift in TMS B3LYP/6-311+G(2d, p) (Figs. 2c, 2d).

The CS tensors are yielded by the quantum chemical calculations in principal axes system to estimate the isotropic chemical-shielding (CSI) and anisotropic chemical-shielding (CSA) [83]:

$$\text{CSI}(\text{ppm}) = (\sigma_{33} + \sigma_{22} + \sigma_{11})/3, \quad (1)$$

$$\text{CSA}(\text{ppm}) = \sigma_{33} - (\sigma_{22} + \sigma_{11})/2. \quad (2)$$

Besides, the Onsager model has influenced on the nuclear magnetic resonance data and chemical shielding of H, C, N, O, F, P atoms in 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 (Figs. 2a, 2b). It has been indicated that oxygen atom in 5AEL, 4PF, 2F92, 2I19 (Fig. 2a) and nitrogen atom in 3DYG, 5AFX (Fig. 2b) has the most effect on the NMR shielding which direct us

toward the active site for adsorption onto (5,5) armchair SWCNT.

In the next step, the results of ^1H -NMR spectroscopy in Fig. 3 has shown the fluctuation of chemical shielding using nuclear magnetic resonance for chelated bisphosphonates of 5AEL- Mg^{2+} , 5AFX- Mg^{2+} , 4QPF- Ca^{2+} , 3DYG- Ca^{2+} , 2F92- Sr^{2+} , and 2I19- Sr^{2+} . As a matter of fact, the bisphosphonate agent of 5AEL- Mg^{2+} and 5AFX- Mg^{2+} have shown the NMR shielding between 0–500 ppm with a sharp peak in 30 ppm and several weak peaks between 150–500 ppm. 4QPF- Ca^{2+} and 3DYG- Ca^{2+} have displayed the NMR shielding between 0–500 ppm with a sharp peak in 25 ppm and several weak peaks between 150–500 ppm. Finally, 2F92- Sr^{2+} and 2I19- Sr^{2+} have presented the NMR shielding between 0–400 ppm with a sharp peak in 25 ppm and several weak peaks between 150–400 ppm.

The perspective of Fig. 3 recommends the reason for existing observed various results of 5AEL- Mg^{2+} , 5AFX- Mg^{2+} , 4QPF- Ca^{2+} , 3DYG- Ca^{2+} , 2F92- Sr^{2+} , and 2I19- Sr^{2+} complexes chelation adsorbed onto (5,5) armchair SWCNT which present the position of active sites of labeled nitrogen, phosphorus, oxygen,

Table 2. Calculated functions of harmonic frequencies (cm^{-1}), IR intensities (km/mol) in different normal modes; thermodynamic properties of ΔG , ΔH in kcal/mol and ΔS in cal/(mol K) at 300 K and optimized energy of UV–Vis spectrum for chelated bisphosphonate agents of 4QPF- Ca^{2+} , 2F92- Sr^{2+} , 2I19- Sr^{2+}

Compounds	Normal mode	IR Intensity, km/mol	Frequency, cm^{-1}	$\Delta G \times 10^{-3}$	$\Delta H \times 10^{-3}$	ΔS	$E_{\text{UV-Vis}} \times 10^{-3}$, kcal/mol
4QPF- Ca^{2+}	26	24.4465	162.0906	-1045.171	-1045.139	107.498	-111.235
	31	85.3674	356.5734				
	34	332.3113	486.0401				
	35	207.0099	496.4700				
	38	104.2123	595.6733				
	45	150.3644	727.1768				
	66	114.3697	1381.9960				
	69	83.8321	1520.5128				
	76	336.2025	1885.8206				
	79	146.3144	2013.8536				
	82	154.2183	3602.2892				
	90	115.0426	4581.3062				
2F92- Sr^{2+}	92	112.2436	4757.1660	-879.212	-879.175	125.093	-86.308
	33	27.6636	740.9208				
	34	100.7688	761.2168				
	37	38.7864	810.6012				
	41	38.6270	1101.6055				
	42	36.8377	1115.9542				
	44	29.6993	1170.0478				
2I19- Sr^{2+}	58	19.0716	1758.7708	-936.261	-936.225	119.524	-94.414
	27	28.6466	399.0835				
	29	34.5129	500.8238				
	33	40.0477	652.4504				
	38	28.0249	789.6133				
	45	32.7104	1084.1391				
	47	31.9705	1110.2915				
	49	38.2129	1142.3353				
	54	57.6366	1302.2768				
	62	106.4028	1673.4444				
	63	75.6871	1681.3981				
	67	49.6146	1986.3383				
	68	200.6094	2058.2918				
	69	126.8656	2742.2821				
	70	173.2174	3408.0867				
	76	320.7285	3765.4924				

fluorine, and metal cations of magnesium, calcium and strontium in these molecules which move the charge of electrons in polar bisphosphonates toward (5,5) armchair carbon nanotube.

IR Method

The infrared (IR) calculations have been accomplished for bisphosphonate agents adsorbed onto (5,5) armchair SWCNT using B3LYP method and basis sets of 6-311+G(2d, p) for metal cations and 6-311+G(2d, p) for other atoms including to obtain the more accurate equilibrium geometrical parameters, thermodynamic

properties and data for each of the determined structure. The IR spectrum for each of two bisphosphonate agents of 2F92 and 2I19 has been seen in the frequency range about 0–4700 cm^{-1} (Fig. 4). Figure 4a has shown the strongest allowed peaks about 350, 750, 1100, 4600 cm^{-1} for 2F92- Sr^{2+} agent and Fig. 4b has indicated the highest frequency at 1650, 2100, 2750, 3400, 3750 cm^{-1} for 2I19- Sr^{2+} , respectively.

Figure 4 demonstrates the relationship between intensity and frequency of 2F92- Sr^{2+} and 2I19- Sr^{2+} bisphosphonate agents in different normal modes of sharp peaks at B3LYP/6-311+G(2d, p) method. The

Table 3. Thermo-physical characteristics of chelated agents of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 with each of metal cations of Mg^{2+} , Ca^{2+} , and Sr^{2+} , respectively adsorbed onto (5,5) armchair SWCNT at 300 K

Agent	Metal cation	Relative energy $\times 10^{-4}$, kcal/mol	Virial coefficient ($-V/T$)	Dipole moment, Debye
5AEL	Mg^{2+}	-96.1388	1.7742	145.3358
	Ca^{2+}	-121.9901	1.7812	1300.1667
	Sr^{2+}	-287.8302	1.9532	1493.9256
5AFX	Mg^{2+}	-95.3258	1.7315	107.7522
	Ca^{2+}	-125.3981	1.7935	2324.3810
	Sr^{2+}	-278.3101	1.9021	2167.8034
4QPF	Mg^{2+}	-111.8961	1.9775	1129.6319
	Ca^{2+}	-143.1309	1.9718	400.0616
	Sr^{2+}	-278.6289	1.9322	996.8129
3DYG	Mg^{2+}	-97.5459	1.8519	842.3853
	Ca^{2+}	-128.6732	1.8940	866.5176
	Sr^{2+}	-292.4445	1.9955	218.6805
2F92	Mg^{2+}	-93.4189	1.9444	597.7910
	Ca^{2+}	-127.7160	1.9794	182.2738
	Sr^{2+}	-277.3898	1.9909	609.9441
2I19	Mg^{2+}	-91.2341	1.8483	601.3917
	Ca^{2+}	-119.3336	1.8754	476.6908
	Sr^{2+}	-285.0652	1.9994	548.9973


calculations of the relative harmonic frequencies, IR intensities, and ΔH , ΔG , ΔS for active points of 4QPF- Ca^{2+} , 2F92- Sr^{2+} , 2I19- Sr^{2+} proteins which have been reported in Table 2 and plotted in Figs. 4, 5.

It has been notable that polarization functions into the applied basis set in the computations always have a significant achievement on the simulation and modeling methods of theoretical levels. The normal mode of spectra is exploring of harmonic potential wells by analytic methods which keep the movement of all atoms at the same time in the vibration time scale leading to a natural definition of molecular vibrations (Fig. 5).

Therefore, the physico-chemical properties of relative energy (kcal/mol), virial coefficient ($-V/T$) and dipole moment (Debye) have determined the stability of bisphosphonate agents among the chelated bisphosphonates including 5AEL- Mg^{2+} , 5AEL- Ca^{2+} , 5AEL- Sr^{2+} ; 5AFX- Mg^{2+} , 5AFX- Ca^{2+} , 5AFX- Sr^{2+} ; 4QPF- Mg^{2+} , 4QPF- Ca^{2+} , 4QPF- Sr^{2+} ; 3DYG- Mg^{2+} , 3DYG- Ca^{2+} , 3DYG- Sr^{2+} ; 2F92- Mg^{2+} , 2F92- Ca^{2+} , 2F92- Sr^{2+} ; 2I19- Mg^{2+} , 2I19- Ca^{2+} , 2I19- Sr^{2+} adsorbed onto (5,5) armchair SWCNT as the drugs for preventing the loss of bone cells, cure osteoporosis and other related diseases through the chelated bonding of these compounds with metal cations of Mg^{2+} , Ca^{2+} , and Sr^{2+} using the drug design method (Table 3 and Fig. 6).

The calculated properties describe solubility and permeability for selected bisphosphonates through biological membranes which appear as efficient bio-availability indicators of investigated bisphosphonates which can be a sufficient methodology to consider in biopharmaceutical classification system (BCS) progress.

Figure 6 has exhibited that the six atoms of oxygen in each site of the bisphosphonate agents chelated to metal cations of 5AEL- Mg^{2+} , 5AEL- Ca^{2+} , 5AEL- Sr^{2+} ; 5AFX- Mg^{2+} , 5AFX- Ca^{2+} , 5AFX- Sr^{2+} ; 4QPF- Mg^{2+} , 4QPF- Ca^{2+} , 4QPF- Sr^{2+} ; 3DYG- Mg^{2+} ,

**Fig. 5.** Calculated IR intensity (km/mol) versus frequency (cm^{-1}) for 4QPF- Ca^{2+} bisphosphonate agent adsorbed onto (5,5) armchair SWCNT using 6-311+G(2d, p) calculations.




Fig. 6. (a) Relative energy versus virial coefficient ($-V/T$), (b) dipole moment changes for chelated agents of 5AEL, 5AFX, 4QPF, 3DYG, 2F92, 2I19 with each metal cations of Mg^{2+} , Ca^{2+} , and Sr^{2+} adsorbed onto (5,5)-SWCNT.

3DYG- Ca^{2+} , 3DYG- Sr^{2+} ; 2F92- Mg^{2+} , 2F92- Ca^{2+} , 2F92- Sr^{2+} ; 2I19- Mg^{2+} , 2I19- Ca^{2+} , 2I19- Sr^{2+} have been minimized by ab-initio method using DFT level which includes ECP calculations with theoretical levels of LANL2DZ for metal elements.

Strontium (Sr) is known for its capability to increase bone and teeth mineralization, osteogenesis, and angiogenesis and downgrading osteoclast activity. This element as one of the main compounds of the bone tissues has a direct impact on metabolism of the

bone. For improving bone cure, various investigations have concentrated on the substitution of calcium ions by strontium ions in the structure of bioactive glasses which can be used for cure of vertebral complex fractures [84, 85].

The results of the above observations strongly suggest that the different data observed of 5AEL- Mg^{2+} , 5AEL- Ca^{2+} , 5AEL- Sr^{2+} ; 5AFX- Mg^{2+} , 5AFX- Ca^{2+} , 5AFX- Sr^{2+} ; 4QPF- Mg^{2+} , 4QPF- Ca^{2+} , 4QPF- Sr^{2+} ; 3DYG- Mg^{2+} , 3DYG- Ca^{2+} , 3DYG- Sr^{2+} ; 2F92- Mg^{2+} ,

2F92-Ca²⁺, 2F92-Sr²⁺; 2I19-Mg²⁺, 2I19-Ca²⁺, 2I19-Sr²⁺ in the solvent is predominantly due to basis set functions are induced by a change in polarity of the environment. It is clear that an increase in the dielectric constants increases the stability and efficiency of these bisphosphonate drugs for preventing the loss of bone density and osteoporosis remedy.

CONCLUSIONS

Bisphosphonate agents have attracted much attention for the clinical treatment of some skeletal diseases depicted by enhancing of osteoclast-mediated bone resorption. According to this research, by incorporation of chelated magnesium, calcium and strontium ions to bisphosphonate drugs adsorbed onto (5,5) armchair SWCNT, the network compaction would increase owing the larger atomic radius of strontium atom rather than calcium and magnesium, respectively.

For improving bone cure, various investigations have concentrated on the substitution of calcium ions by strontium ions in the structure of bioactive glasses which can be used for cure of vertebral complex fractures.

ACKNOWLEDGMENTS

We thank our colleagues who provided insight and expertise that greatly assisted the research, and we would also like to extend our thanks to Department of Orthopedics and Traumatology, and Department of Physical Medicine and Rehabilitation from Faculty of Medicine in Kastamonu University.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. M. Kistler-Fischbacher, B. K. Weeks, and B. R. Beck, *Bone* **143**, 115697 (2021).
<https://doi.org/10.1016/j.bone.2020.115697>
2. K. E. Åkesson and F. E. A. McGuigan, *Curr. Osteoporos. Rep.* **19**, 58 (2021).
<https://doi.org/10.1007/s11914-020-00644-w>
3. G. Tiwari, R. Tiwari, B. Sriwastawa, et al., *Int. J. Pharm. Invest.* **2**, 2 (2012).
<https://doi.org/10.4103/2230-973X.96920>
4. J. Li, M. Zeng, H. Shan, and C. Tong, *Curr. Med. Chem.* **2**, 2413 (2017).
<https://doi.org/10.2174/0929867324666170526124053>
5. R. K. Tekade, *Basic Fundamentals of Drug Delivery* (Elsevier, Amsterdam, 2018).
6. T. M. Allen, *Science* (Washington, DC, U. S.) **303**, 1818 (2004).
<https://doi.org/10.1126/science.1095833>
7. A. P. Singh, A. Biswas, A. Shukla, and P. Maiti, *Signal Transduct. Target. Ther.* **4**, 33 (2019).
<https://doi.org/10.1038/s41392-019-0068-3>
8. M. Monajjemi, B. Honaparvar, B. Khalili Hadad, et al., *Afr. J. Pharm. Pharmacol.* **4**, 521 (2010).
9. A. Tahan, F. Mollaamin, and M. Monajjemi, *Russ. J. Phys. Chem. A* **83**, 587 (2009).
<https://doi.org/10.1134/S003602440904013X>
10. K. Bakhshi, F. Mollaamin, and M. Monajjemi, *J. Comput. Theor. Nanosci* **8**, 763 (2011).
<https://doi.org/10.1166/jctn.2011.1750>
11. M. Monajjemi, M. T. Baie, and F. Mollaamin, *Russ. Chem. Bull.* **59**, 886 (2010).
<https://doi.org/10.1007/s11172-010-0181-5>
12. B. Khalili Hadad, F. Mollaamin, and M. Monajjemi, *Russ. Chem. Bull.* **60**, 238 (2022).
<https://doi.org/10.1007/s11172-011-0039-5>
13. S. M. N. Mohsin, M. Z. Hussein, S. H. Sarijo, et al., *Sci. Adv. Mater.* **6**, 648 (2014).
14. B. Saifullah, M. Z. Hussein, S. H. Hussein-Al-Ali, et al., *Drug Des. Develop. Ther.* **7**, 1365 (2013).
15. F. Barahuie, M. Z. Hussein, S. H. Hussein-Al-Ali, et al., *Int. J. Nanomed.* **8**, 1975 (2013).
16. A. U. Kura, S. H. Hussein-Al-Ali, M. Z. Hussein, et al., *Int. J. Nanomed.* **8**, 1103 (2013).
17. S. M. N. Mohsin, M. Z. Hussein, S. H. Sarijo, et al., *Chem. Centr. J.* **7**, 26 (2013).
18. S. M. N. Mohsin, M. Z. Hussein, S. H. Sarijo, et al., *J. Biomed. Nanotechnol.* **10**, 1490 (2014).
19. X. Cao, W. Deng, M. Fu, et al., *J. Pharm. Sci.* **48**, 64 (2013).
20. R. Ghaffarian, T. Bhowmick, and S. J. Muro, *Control. Release* **163**, 25 (2012).
21. L. Zhang, H. Xue, Z. Cao, et al., *Biomaterials* **32**, 4604 (2011).
22. D. S. Bethune, C. H. Kiang, M. S. de Vries, et al., *Nature* (London, U. K.) **363**, 605 (1993).
23. S. Iijima and T. Ichihashi, *Nature* (London, U.K.) **363**, 603 (1993).
24. H. Dai, *Surf. Sci.* **500**, 218 (2002).
25. T. G. Abi, T. Karmakar, and S. Taraphder, *Comput. Theor. Chem.* **1010**, 53 (2013).
26. W. Feng and P. Ji, *Biotechnol. Adv.* **29**, 889 (2011).
27. Q. Chen, T. Kaneko, and R. Hatakeyama, *Curr. Appl. Phys.* **11**, S63 (2011).
28. B. Ghalandari, M. Monajjemi, and F. Mollaamin, *J. Comput. Theor. Nanosci* **8**, 1212 (2011).
<https://doi.org/10.1166/jctn.2011.1801>
29. M. Khaleghian, M. Zahmatkesh, F. Mollaamin, and M. Monajjemi, *Fullerenes Nanotubes Carbon Nanostruct.* **19**, 251 (2011).
<https://doi.org/10.1080/15363831003721757>
30. M. Monajjemi, M. Khaleghian, N. Tadayonpour, and Mollaamin, *Int. J. Nanosci.* **09**, 517 (2010).
<https://doi.org/10.1142/S0219581X10007071>
31. F. Mollaamin, M. Monajjemi, S. Salemi, and M. T. Baei, *Fullerenes Nanotubes Carbon Nanostruct.* **19**, 182 (2011).
<https://doi.org/10.1080/15363831003782932>

32. M. Monajjemi, B. Honaparvar, B. Khalili Hadad, et al., *Afr. J. Pharm. Pharmacol.* **4**, 521 (2010).
33. S. Sapino, G. Chindamo, D. Chirio, et al., *Nanomaterials* **11**, 2983 (2021).
<https://doi.org/10.3390/nano11112983>
34. J. Park, A. Cimpean, A. B. Tesler, and A. Mazare, *Nanomaterials* **11**, 2359 (2021).
<https://doi.org/10.3390/nano11092359>
35. L. Gao and S.-Q. Zhang, *Pharmaceuticals* **15**, 397 (2022).
<https://doi.org/10.3390/ph15040397>
36. G. Chindamo, S. Sapino, E. Peira, et al., *Nanomaterials* **10**, 875 (2020).
<https://doi.org/10.3390/nano10050875>
37. F. Salamanna, A. Gambardella, D. Contartese, et al., *Nanomaterials* **11**, 530 (2021).
<https://doi.org/10.3390/nano11020530>
38. S. Choi, H.-S. Jo, H. Song, et al., *Nanomaterials* **11**, 1812 (2021).
<https://doi.org/10.3390/nano11071812>
39. M. Monajjemi, *BioPhys. Chem.* **207**, 114 (2015).
<https://doi.org/10.1016/j.bpc.2015.10.003>
40. L. Mahdavian and M. Monajjemi, *Microelectron. J.* **41**, 142 (2010).
<https://doi.org/10.1016/j.mejo.2010.01.011>
41. M. Monajjemi, N. Farahani, and F. Mollaamin, *Phys. Chem. Liq.* **50**, 161 (2012).
<https://doi.org/10.1080/00319104.2010.527842>
42. E. M. Sarasia, S. Afsharnezhad, B. Honarparvar, et al., *Phys. Chem. Liq.* **49**, 561 (2011).
<https://doi.org/10.1080/00319101003698992>
43. M. Monajjemi, *J. Mol. Liq.* **230**, 461 (2017).
<https://doi.org/10.1016/j.molliq.2017.01.044>
44. F. Mollaamin, A. R. Ilkhani, N. Sakhaei, et al., *J. Comput. Theor. Nanosci.* **12**, 3148 (2015).
<https://doi.org/10.1166/jctn.2015.4092>
45. Z. Mbese and B. A. Aderibigbe, *Int. J. Mol. Sci.* **22**, 6869 (2021).
<https://doi.org/10.3390/ijms22136869>
46. M. Rauner, H. Taipaleenmäki, E. Tsourdi, and E. M. Winter, *J. Clin. Med.* **10**, 787 (2021).
<https://doi.org/10.3390/jcm10040787>
47. I. Geiger, C. Kammerler, C. Höfer, et al., *BMC Geriatr.* **21**, 43 (2021).
<https://doi.org/10.1186/s12877-020-01966-1>
48. K. N. Hayes, N. He, K. A. Brown, et al., *Osteoporos. Int.* **32**, 1413 (2021).
<https://doi.org/10.1007/s00198-020-05794-2>
49. A. S. Sølling, D. H. Christensen, B. Darvalics, et al., *Osteoporos. Int.* **32**, 1103 (2021).
<https://doi.org/10.1007/s00198-020-05745-x>
50. J.-W. Kim, J. Yee, S.-H. Oh, et al., *J. Pers. Med.* **11**, 541 (2021).
<https://doi.org/10.3390/jpm11060541>
51. B. L. Langdahl, *Br. J. Pharmacol.* **178**, 1891 (2021).
<https://doi.org/10.1111/bph.15024>
52. L. Widler, K. A. Jaeggi, M. Glatt, et al., *J. Med. Chem.* **45**, 3721 (2002).
<https://doi.org/10.1021/jm020819i>
53. K. Thompson and M. J. Rogers, *Clin. Rev. Bone Miner. Metabolism* **5**, 130 (2007).
<https://doi.org/10.1007/s12018-007-9004-0>
54. R. G. Russell, N. B. Watts, F. H. Ebetino, and M. Rogers, *J. Osteoporos. Int.* **19**, 733 (2008).
55. R. G. Russell, *Bone* **49**, 2 (2011).
56. A. M. Quesnel, M. Seton, S. N. Merchant, et al., *Otol. Neurotol.* **33**, 1308 (2012).
<https://doi.org/10.1097/MAO.0b013e318268d1b3>
57. A. Diez-Perez, *Maturitas* **43**, S19 (2002).
[https://doi.org/10.1016/s0378-5122\(02\)00145-7](https://doi.org/10.1016/s0378-5122(02)00145-7)
58. L. M. Rodríguez-Lorenzo, B. Vazquez, J. San Román, and K. A. Gross, *Key Eng. Mater.* **309–311**, 899 (2006).
59. M. T. Drake, B. L. Clarke, and S. Khosla, *Clin. Mayo Clin. Proc.* **83**, 1032 (2008).
<https://doi.org/10.4065/83.9.1032>
60. D. M. Black, P. D. Delmas, R. Eastell, et al., *N. Engl. J. Med.* **356**, 1809 (2007).
61. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, et al., *Gaussian 2009* (Gaussian, Inc., Wallingford, CT, 2009).
62. W. Koch and M. C. Holthausen, *A Chemist's Guide to Density Functional Theory*, 2nd ed. (Wiley-VCH, Weinheim, 2000), pp. 3, 93.
63. M. Monajjemi, *Biointerface Res. Appl. Chem.* **3**, 5575 (2020).
<https://doi.org/10.33263/BRIAC103.575585>
64. M. A. A. Zadeh, H. Lari, L. Kharghanian, et al., *J. Comput. Theor. Nanosci.* **12**, 4358 (2015).
<https://doi.org/10.1166/jctn.2015.4366>
65. M. Monajjemi, S. Shahriari, and F. Mollaamin, *Biointerface Res. Appl. Chem.* **10**, 6039 (2020).
<https://doi.org/10.33263/BRIAC105.60396057>
66. A. D. Becke, *J. Chem. Phys.* **98**, 5648 (1993).
67. C. Lee, W. Yang, and R. G. Parr, *Phys. Rev. B* **37**, 785 (1988).
68. C. J. Cramer and D. G. Truhlar, *J. Comput. Chem.* **13**, 1089 (1992).
69. D. A. Liotard, G. D. Hawkins, G. C. Lynch, et al., *J. Comput. Chem.* **16**, 422 (1995).
70. C. C. Chambers, G. D. Hawkins, C. J. Cramer, and D. G. Truhlar, *J. Phys. Chem.* **100**, 16385 (1996).
71. D. J. Giesen, M. Z. Gu, C. J. Cramer, and D. G. Truhlar, *J. Org. Chem.* **61**, 8720 (1996).
72. L. J. Onsager, *J. Am. Chem. Soc.* **58**, 1486 (1936).
73. J. Tomasi, *J. Theor. Chem. Acc.* **103**, 196 (2000).
74. J. Park, V. R. Pandya, and S. J. Ezekiel, *Front. Chem.* **8**, 612728 (2021).
<https://doi.org/10.3389/fchem.2020.612728>
75. C. Marocco, G. Zimatore, E. Mocini, et al., *Int. J. Environ. Res. Publ. Health* **18**, 1728 (2021).
<https://doi.org/10.3390/ijerph18041728>
76. F. H. Ebetino, S. Sun, P. Cherian, et al., *Bone* **156**, 116289 (2022).
<https://doi.org/10.1016/j.bone.2021.116289>
77. G. Yang, W. Zhu, K. Kim, et al., *Antimicrob. Agents Chemother.* **59**, 7530 (2015).
<https://doi.org/10.1128/AAC.01873-15>

78. E. Adjei-Sowah, Y. Peng, J. Weeks, et al., *Antibiotics* **10**, 732 (2021).
<https://doi.org/10.3390/antibiotics10060732>
79. S. Tanaka and Y. Tanaka, *J. Bone Miner. Metab.* **39**, 106 (2021).
<https://doi.org/10.1007/s00774-020-01159-1>
80. M. Vassaki, C. Kotoula, P. Turhanen, et al., *Appl. Sci.* **11**, 11383 (2021).
<https://doi.org/10.3390/app112311383>
81. L. Rauch, R. Hein, T. Biedermann, et al., *Biomedicines* **9**, 1698 (2021).
<https://doi.org/10.3390/biomedicines9111698>
82. M. Monajjemi, *J. Mol. Model.* **20**, 2507 (2014).
<https://doi.org/10.1007/s00894-014-2507-y>
83. A. Fry, D. Kwon, K. Komarneni, et al., *Langmuir* **22**, 9281 (2006).
84. B. Kołodziejska and N. Stępień, and Kolmas, *Int. J. Mol. Sci.* **22**, 6564 (2021).
<https://doi.org/10.3390/ijms22126564>
85. D. Marx, A. R. Yazdi, M. Papini, and M. Towler, *Bone Rep.* **12**, 100273 (2020).
<https://doi.org/10.1016/j.bonr.2020.100273>